Rare transmission of hepatitis A virus through blood transfusion products

Česká verze

Authors: L. Petroušová ¹ ; J. Smetana ² ; B. Hrstková ¹; Z. Čermáková ³ ; R. Chlíbek ²
Authors place of work: Klinika infekčního lékařství, Fakultní nemocnice Ostrava a Lékařská fakulta Ostravská univerzita ¹; Katedra epidemiologie, Vojenská lékařská fakulta Univerzity obrany, Hradec Králové ²; Krevní centrum, Fakultní nemocnice Ostrava a Lékařská fakulta Ostravská univerzita ³
Published in the journal: Epidemiol. Mikrobiol. Imunol. 75, 2026, č. 2, s. 99-102
Category: Krátká sdělení
doi: https://doi.org/10.61568/emi/11-6717/20260323/143213

Summary

Viral hepatitis A (VHA) is primarily transmitted via the faecal-oral route. Transmission through blood transfusion products is rare. In 2025, during an ongoing VHA epidemic in the Czech Republic, cases of hepatitis A virus (HAV) transmission through transfusion blood products from an asymptomatic donor were detected. The donor was only found to be HAV positive after developing clinical symptoms. Infected blood transfusion products (leukocyte-depleted erythrocytes and thrombocytes) were administered to two recipients, who subsequently developed infection. One of them, a paediatric patient, presented with anicteric VHA without complications, while the other immunocompromised patient had prolonged viremia. These cases highlight the risk of HAV transmission through blood transfusions, particularly during epidemics. Asymptomatic viremia in donors makes it impossible to detect infection without targeted testing. The introduction of direct nucleic acid testing (NAT) for HAV during a period of increased incidence of infection would improve the safety of blood transfusions.

Keywords:

viral hepatitis A – infected transfusion products – screening of blood donors

Zdroje

1. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2019. 4176 p. ISBN-13 : 978-0323482554.

2. Hughes JA, Fontaine MJ, Gonzalez CL, et al. Case report of a transfusion-associated hepatitis A infection. Transfusion. 2014;54(9):2202–2206. DOI: 10.1111/trf.12648.

3. Gowland P, Fontana S, Niederhauser C, et al. Molecular and serologic tracing of a transfusion-transmitted hepatitis A virus. Transfusion. 2004;44(11):1555–1561. DOI: 10.1111/j. 1537-2995.2004.04071.x.

4. Lefeuvre C, Lefort C, Boyer F et al. Transfusion-transmitted hepatitis A virus, France, 2018. Emerg Infect Dis., 2022;28(1):219–223. DOI: 10.3201/eid2801.210403.

5. Státní zdravotní ústav Praha. Výskyt vybraných hlášených infekcí podle věkových skupin v České republice. Dostupné na www: https://szu.gov.cz/wp-content/uploads/2026/01/Vekove_skupiny_2018-2025_pocty-onemocneni.pdf.

6. European Centre for Disease Prevention and Control. Rapid risk assessment: multi country outbreak of hepatitis A in the EU/ EEA: 18 June 2025. Aviable in https://www.ecdc.europa.eu/en/ publications-data/rapid-risk-assessment-multi-country-outbreak-hepatitis-eueea.

7. Polański P, Kucharczyk B, Kondej B et al. Hepatitis A in Poland in 2017 –⁠ epidemic increase cases. Przegl Epidemiol. 2019;73(4):487–497. DOI: 10.32394/pe.73.46.

8. Sulkowska E, Masny A, Kalińska A, et al. Hepatitis A virus (HAV) RNA detection in Polish blood donors and likely transmissions through blood components during the 2017–2019 epidemic. Transfusion, 2023;63(2):349–359. DOI: 10.1111/trf.17225.

9. Vyhláška č. 143/2008 Sb. Vyhláška o stanovení bližších požadavků pro zajištění jakosti a bezpečnosti lidské krve a jejích složek (vyhláška o lidské krvi). Dostupné na www: https://www.zakonyprolidi.cz/cs/2008-143.

10. da Silva SGC, Leon LAA, Alves G, et al. A rare case of transfusion transmission of hepatitis A virus to two patients with haematological disease. Transfus Med Hemother. 2016;43(2):137–141. DOI: 10.1159/000441910.